Key clinical point: The disease severity assessment, guiding initiation of systemic therapy, differed when either patient- or clinician-reported outcomes were considered alone, highlighting the complementary value of both for appropriate treatment.

Major finding: Overall, 72.4% (95% confidence interval [CI], 67.3%-77.0%) of patients who qualified for systemic therapy initiation on account of Psoriasis Area Severity Index (PASI) scores or body surface area (BSA) of 10 or higher had a Dermatology Life Quality Index (DLQI) score of less than 10. Conversely, 10.4% (95% CI, 8.8%-12.1%) of patients with a DLQI score higher than 10 did not qualify for systemic therapy based on PASI scores or BSA.

Study details: Findings are from a cross-sectional, observational study including 1,733 patients with mild, moderate, or severe psoriasis who met the criteria for initiation of systemic therapy based on DLQI score, PASI score, or BSA.

Disclosures: No specific funding for the study was disclosed. Dr. Gelfand declared receiving consultation fees and research grants from various sources.

Source: Barbieri JS et al. JAMA Dermatol. 2021 Sep 8. doi: 10.1001/jamadermatol.2021.3341.

Key clinical point: The disease severity assessment, guiding initiation of systemic therapy, differed when either patient- or clinician-reported outcomes were considered alone, highlighting the complementary value of both for appropriate treatment.

Major finding: Overall, 72.4% (95% confidence interval [CI], 67.3%-77.0%) of patients who qualified for systemic therapy initiation on account of Psoriasis Area Severity Index (PASI) scores or body surface area (BSA) of 10 or higher had a Dermatology Life Quality Index (DLQI) score of less than 10. Conversely, 10.4% (95% CI, 8.8%-12.1%) of patients with a DLQI score higher than 10 did not qualify for systemic therapy based on PASI scores or BSA.

Study details: Findings are from a cross-sectional, observational study including 1,733 patients with mild, moderate, or severe psoriasis who met the criteria for initiation of systemic therapy based on DLQI score, PASI score, or BSA.

Disclosures: No specific funding for the study was disclosed. Dr. Gelfand declared receiving consultation fees and research grants from various sources.

Source: Barbieri JS et al. JAMA Dermatol. 2021 Sep 8. doi: 10.1001/jamadermatol.2021.3341.

Key clinical point: The disease severity assessment, guiding initiation of systemic therapy, differed when either patient- or clinician-reported outcomes were considered alone, highlighting the complementary value of both for appropriate treatment.

Major finding: Overall, 72.4% (95% confidence interval [CI], 67.3%-77.0%) of patients who qualified for systemic therapy initiation on account of Psoriasis Area Severity Index (PASI) scores or body surface area (BSA) of 10 or higher had a Dermatology Life Quality Index (DLQI) score of less than 10. Conversely, 10.4% (95% CI, 8.8%-12.1%) of patients with a DLQI score higher than 10 did not qualify for systemic therapy based on PASI scores or BSA.

Study details: Findings are from a cross-sectional, observational study including 1,733 patients with mild, moderate, or severe psoriasis who met the criteria for initiation of systemic therapy based on DLQI score, PASI score, or BSA.

Disclosures: No specific funding for the study was disclosed. Dr. Gelfand declared receiving consultation fees and research grants from various sources.

Source: Barbieri JS et al. JAMA Dermatol. 2021 Sep 8. doi: 10.1001/jamadermatol.2021.3341.

Key clinical point: Risankizumab displayed superior long-term clinical efficacy against moderate-to-severe psoriasis, with no new safety signals in the 52-week update of a multicenter real-life study.

Major finding: Psoriasis Area and Severity Index (PASI) 75, PASI 90, and PASI 100 response rates at week 36 were 92.7%, 83.6%, and 65.5%, which were maintained through week 52 at 96.4%, 85.5%, and 60.0%, respectively. Unlike in phase 3 trials, more biologic-experienced patients reached PASI 100 at weeks 36 and 52 (71.8% and 69.2%, respectively) compared with biologic-naïve patients (50.0% and 37.5%, respectively).

Study details: Findings are from a real-life multicenter study including 57 adult patients with moderate-to-severe psoriasis who were receiving risankizumab therapy.

Disclosures: The study did not receive any funding. Some of the authors including the lead author declared receiving consultation/personal fees or research grants from various sources.

Source: Hansel K et al. J Eur Acad Dermatol Venereol. 2021 Sep 12. doi: 10.1111/jdv.17656.

Key clinical point: Risankizumab displayed superior long-term clinical efficacy against moderate-to-severe psoriasis, with no new safety signals in the 52-week update of a multicenter real-life study.

Major finding: Psoriasis Area and Severity Index (PASI) 75, PASI 90, and PASI 100 response rates at week 36 were 92.7%, 83.6%, and 65.5%, which were maintained through week 52 at 96.4%, 85.5%, and 60.0%, respectively. Unlike in phase 3 trials, more biologic-experienced patients reached PASI 100 at weeks 36 and 52 (71.8% and 69.2%, respectively) compared with biologic-naïve patients (50.0% and 37.5%, respectively).

Study details: Findings are from a real-life multicenter study including 57 adult patients with moderate-to-severe psoriasis who were receiving risankizumab therapy.

Disclosures: The study did not receive any funding. Some of the authors including the lead author declared receiving consultation/personal fees or research grants from various sources.

Source: Hansel K et al. J Eur Acad Dermatol Venereol. 2021 Sep 12. doi: 10.1111/jdv.17656.

Key clinical point: Risankizumab displayed superior long-term clinical efficacy against moderate-to-severe psoriasis, with no new safety signals in the 52-week update of a multicenter real-life study.

Major finding: Psoriasis Area and Severity Index (PASI) 75, PASI 90, and PASI 100 response rates at week 36 were 92.7%, 83.6%, and 65.5%, which were maintained through week 52 at 96.4%, 85.5%, and 60.0%, respectively. Unlike in phase 3 trials, more biologic-experienced patients reached PASI 100 at weeks 36 and 52 (71.8% and 69.2%, respectively) compared with biologic-naïve patients (50.0% and 37.5%, respectively).

Study details: Findings are from a real-life multicenter study including 57 adult patients with moderate-to-severe psoriasis who were receiving risankizumab therapy.

Disclosures: The study did not receive any funding. Some of the authors including the lead author declared receiving consultation/personal fees or research grants from various sources.

Source: Hansel K et al. J Eur Acad Dermatol Venereol. 2021 Sep 12. doi: 10.1111/jdv.17656.

Key clinical point: Secukinumab demonstrated a high skin-clearing effect and favorable safety in pediatric patients with moderate-to-severe plaque psoriasis through week 24.

Major finding: At week 12, low dose (LD) and high dose (HD) groups showed a Psoriasis Area Severity Index (PASI) 75 response rate (RR) of 92.9%, whereas their Investigator's Global Assessment (IGA) 0/1 RRs were 78.5% and 83.4%, respectively. At week 24, the PASI 75 RR for LD and HD groups increased to 95.2% and IGA 0/1 RRs increased to 88.1% and 92.9%, respectively. Both groups displayed similar treatment-emergent adverse events.

Study details: These are 24-week findings of a 224-week, open-label, phase 3 study including 84 pediatric patients with moderate-to-severe plaque psoriasis randomly assigned to LD or HD secukinumab (75/75/150 or 75/150/300 mg for body weight (kg) less than 25/25 to less than 50/50 or more, respectively).

Disclosures: The study was sponsored by Novartis Pharma AG, Switzerland. R Mazur, P Forrer, and M Patekar declared being employees of Novartis Pharma AG. Some of the authors declared serving on advisory board, speaker, consultant, or principal/subinvestigator for various organizations including Novartis.

Source: Magnolo N et al. J Am Acad Dermatol. 2021 Sep 20. doi: 10.1016/j.jaad.2021.08.066.

Key clinical point: Secukinumab demonstrated a high skin-clearing effect and favorable safety in pediatric patients with moderate-to-severe plaque psoriasis through week 24.

Major finding: At week 12, low dose (LD) and high dose (HD) groups showed a Psoriasis Area Severity Index (PASI) 75 response rate (RR) of 92.9%, whereas their Investigator's Global Assessment (IGA) 0/1 RRs were 78.5% and 83.4%, respectively. At week 24, the PASI 75 RR for LD and HD groups increased to 95.2% and IGA 0/1 RRs increased to 88.1% and 92.9%, respectively. Both groups displayed similar treatment-emergent adverse events.

Study details: These are 24-week findings of a 224-week, open-label, phase 3 study including 84 pediatric patients with moderate-to-severe plaque psoriasis randomly assigned to LD or HD secukinumab (75/75/150 or 75/150/300 mg for body weight (kg) less than 25/25 to less than 50/50 or more, respectively).

Disclosures: The study was sponsored by Novartis Pharma AG, Switzerland. R Mazur, P Forrer, and M Patekar declared being employees of Novartis Pharma AG. Some of the authors declared serving on advisory board, speaker, consultant, or principal/subinvestigator for various organizations including Novartis.

Source: Magnolo N et al. J Am Acad Dermatol. 2021 Sep 20. doi: 10.1016/j.jaad.2021.08.066.

Key clinical point: Secukinumab demonstrated a high skin-clearing effect and favorable safety in pediatric patients with moderate-to-severe plaque psoriasis through week 24.

Major finding: At week 12, low dose (LD) and high dose (HD) groups showed a Psoriasis Area Severity Index (PASI) 75 response rate (RR) of 92.9%, whereas their Investigator's Global Assessment (IGA) 0/1 RRs were 78.5% and 83.4%, respectively. At week 24, the PASI 75 RR for LD and HD groups increased to 95.2% and IGA 0/1 RRs increased to 88.1% and 92.9%, respectively. Both groups displayed similar treatment-emergent adverse events.

Study details: These are 24-week findings of a 224-week, open-label, phase 3 study including 84 pediatric patients with moderate-to-severe plaque psoriasis randomly assigned to LD or HD secukinumab (75/75/150 or 75/150/300 mg for body weight (kg) less than 25/25 to less than 50/50 or more, respectively).

Disclosures: The study was sponsored by Novartis Pharma AG, Switzerland. R Mazur, P Forrer, and M Patekar declared being employees of Novartis Pharma AG. Some of the authors declared serving on advisory board, speaker, consultant, or principal/subinvestigator for various organizations including Novartis.

Source: Magnolo N et al. J Am Acad Dermatol. 2021 Sep 20. doi: 10.1016/j.jaad.2021.08.066.

Key clinical point: Stereotactic body radiation therapy (SBRT) is safe and shows low incidence of high-grade bleeding in older patients with localized prostate cancer who received anticoagulant or antiplatelet treatment.

Major finding: Overall, 18.2% of patients reported hematuria with a median time of 10.5 months and 38.6% experienced hematochezia with a median time of 6 months. Rates of grade 2 or more hematuria and hematochezia were 4.6% and 2.5%, respectively. No grade 4 or 5 toxicities were reported.

Study details: A retrospective study of 44 patients with localized prostate cancer (median age, 72 years) who were treated with SBRT between 2007 and 2017 and received anticoagulant or antiplatelet at baseline. Patients with rectal spacer were not included.

Disclosures: The study was funded by Accuray, National Institute on Minority Health and Health Disparities and The James and Theodore Pedas Family Foundation. The authors did not declare any conflict of interests.

Source: Pepin A et al. Front Oncol. 2021 Sep 17. doi: 10.3389/fonc.2021.722852.

Key clinical point: Stereotactic body radiation therapy (SBRT) is safe and shows low incidence of high-grade bleeding in older patients with localized prostate cancer who received anticoagulant or antiplatelet treatment.

Major finding: Overall, 18.2% of patients reported hematuria with a median time of 10.5 months and 38.6% experienced hematochezia with a median time of 6 months. Rates of grade 2 or more hematuria and hematochezia were 4.6% and 2.5%, respectively. No grade 4 or 5 toxicities were reported.

Study details: A retrospective study of 44 patients with localized prostate cancer (median age, 72 years) who were treated with SBRT between 2007 and 2017 and received anticoagulant or antiplatelet at baseline. Patients with rectal spacer were not included.

Disclosures: The study was funded by Accuray, National Institute on Minority Health and Health Disparities and The James and Theodore Pedas Family Foundation. The authors did not declare any conflict of interests.

Source: Pepin A et al. Front Oncol. 2021 Sep 17. doi: 10.3389/fonc.2021.722852.

Key clinical point: Stereotactic body radiation therapy (SBRT) is safe and shows low incidence of high-grade bleeding in older patients with localized prostate cancer who received anticoagulant or antiplatelet treatment.

Major finding: Overall, 18.2% of patients reported hematuria with a median time of 10.5 months and 38.6% experienced hematochezia with a median time of 6 months. Rates of grade 2 or more hematuria and hematochezia were 4.6% and 2.5%, respectively. No grade 4 or 5 toxicities were reported.

Study details: A retrospective study of 44 patients with localized prostate cancer (median age, 72 years) who were treated with SBRT between 2007 and 2017 and received anticoagulant or antiplatelet at baseline. Patients with rectal spacer were not included.

Disclosures: The study was funded by Accuray, National Institute on Minority Health and Health Disparities and The James and Theodore Pedas Family Foundation. The authors did not declare any conflict of interests.

Source: Pepin A et al. Front Oncol. 2021 Sep 17. doi: 10.3389/fonc.2021.722852.

Key clinical point: A single-fraction high-dose-rate (HDR) brachytherapy boost followed by ultra-hypofractionated stereotactic body radiation therapy (SBRT) to the prostate and/or pelvic lymph nodes shows a low rate of early toxicity in patients with higher-risk prostate cancer.

Major finding: The median follow-up was 24.1 months. No grade 3 or worse genitourinary or gastrointestinal toxicities were reported. Acute and late grade 2 gastrointestinal adverse events (AEs) were 0.99% each. Acute and late grade 2 genitourinary AEs were 5.9% and 9.9%, respectively. The median time to a grade 2 genitourinary toxicity was 6 months.

Study details: A retrospective study of 101 patients with high-risk prostate cancer who received HDR brachytherapy combined with ultra-hypofractionated radiotherapy.

Disclosures: This work was supported by the National Institutes of Health. The authors received research funding, consulting fees, and/or honoraria and/or served as editor-in-chief.

Source: Gorovets D et al. Brachytherapy. 2021 Sep 26. doi: 10.1016/j.brachy.2021.08.006.

Key clinical point: A single-fraction high-dose-rate (HDR) brachytherapy boost followed by ultra-hypofractionated stereotactic body radiation therapy (SBRT) to the prostate and/or pelvic lymph nodes shows a low rate of early toxicity in patients with higher-risk prostate cancer.

Major finding: The median follow-up was 24.1 months. No grade 3 or worse genitourinary or gastrointestinal toxicities were reported. Acute and late grade 2 gastrointestinal adverse events (AEs) were 0.99% each. Acute and late grade 2 genitourinary AEs were 5.9% and 9.9%, respectively. The median time to a grade 2 genitourinary toxicity was 6 months.

Study details: A retrospective study of 101 patients with high-risk prostate cancer who received HDR brachytherapy combined with ultra-hypofractionated radiotherapy.

Disclosures: This work was supported by the National Institutes of Health. The authors received research funding, consulting fees, and/or honoraria and/or served as editor-in-chief.

Source: Gorovets D et al. Brachytherapy. 2021 Sep 26. doi: 10.1016/j.brachy.2021.08.006.

Key clinical point: A single-fraction high-dose-rate (HDR) brachytherapy boost followed by ultra-hypofractionated stereotactic body radiation therapy (SBRT) to the prostate and/or pelvic lymph nodes shows a low rate of early toxicity in patients with higher-risk prostate cancer.

Major finding: The median follow-up was 24.1 months. No grade 3 or worse genitourinary or gastrointestinal toxicities were reported. Acute and late grade 2 gastrointestinal adverse events (AEs) were 0.99% each. Acute and late grade 2 genitourinary AEs were 5.9% and 9.9%, respectively. The median time to a grade 2 genitourinary toxicity was 6 months.

Study details: A retrospective study of 101 patients with high-risk prostate cancer who received HDR brachytherapy combined with ultra-hypofractionated radiotherapy.

Disclosures: This work was supported by the National Institutes of Health. The authors received research funding, consulting fees, and/or honoraria and/or served as editor-in-chief.

Source: Gorovets D et al. Brachytherapy. 2021 Sep 26. doi: 10.1016/j.brachy.2021.08.006.

Key clinical point: Use of chemotherapy and survival has increased in contemporary patients with de novo metastatic prostate cancer vs historical patients.

Major finding: The rates of chemotherapy were not significantly different between 2004 and 2013 (P = .3). The chemotherapy rates increased from 17.2% to 24.7% between 2014 and 2016 (P = .04). After propensity score matching, the median overall survival was significantly longer in contemporary vs. historical patients (not reached vs 25 months; adjusted hazard ratio [aHR], 0.55; P < .001). Cancer-specific mortality also improved in contemporary patients (not reached vs. 26 months; aHR, 0.55; P < .001).

Study details: A retrospective study of 19,913 patients who had de novo metastatic prostate cancer between 2004 and 2016, divided between historical (2004-2013) and contemporary (2014-2016).

Disclosures: No funding source was identified for this work. The authors had no competing interests.

Source: Hoeh B et al. Prostate. 2021 Sep 15. doi: 10.1002/pros.24235.

Key clinical point: Use of chemotherapy and survival has increased in contemporary patients with de novo metastatic prostate cancer vs historical patients.

Major finding: The rates of chemotherapy were not significantly different between 2004 and 2013 (P = .3). The chemotherapy rates increased from 17.2% to 24.7% between 2014 and 2016 (P = .04). After propensity score matching, the median overall survival was significantly longer in contemporary vs. historical patients (not reached vs 25 months; adjusted hazard ratio [aHR], 0.55; P < .001). Cancer-specific mortality also improved in contemporary patients (not reached vs. 26 months; aHR, 0.55; P < .001).

Study details: A retrospective study of 19,913 patients who had de novo metastatic prostate cancer between 2004 and 2016, divided between historical (2004-2013) and contemporary (2014-2016).

Disclosures: No funding source was identified for this work. The authors had no competing interests.

Source: Hoeh B et al. Prostate. 2021 Sep 15. doi: 10.1002/pros.24235.

Key clinical point: Use of chemotherapy and survival has increased in contemporary patients with de novo metastatic prostate cancer vs historical patients.

Major finding: The rates of chemotherapy were not significantly different between 2004 and 2013 (P = .3). The chemotherapy rates increased from 17.2% to 24.7% between 2014 and 2016 (P = .04). After propensity score matching, the median overall survival was significantly longer in contemporary vs. historical patients (not reached vs 25 months; adjusted hazard ratio [aHR], 0.55; P < .001). Cancer-specific mortality also improved in contemporary patients (not reached vs. 26 months; aHR, 0.55; P < .001).

Study details: A retrospective study of 19,913 patients who had de novo metastatic prostate cancer between 2004 and 2016, divided between historical (2004-2013) and contemporary (2014-2016).

Disclosures: No funding source was identified for this work. The authors had no competing interests.

Source: Hoeh B et al. Prostate. 2021 Sep 15. doi: 10.1002/pros.24235.

Key clinical point: Bone-modifying agents (BMAs) are overused in the real world in patients with metastatic castration-sensitive prostate cancer (mCSPC).

Major finding: Receipt of BMAs was reported in 23.6% of patients within 180 days of diagnosis. The proportion of patients receiving BMAs within 180 days increased from 17.3% during 2007-2009 to 28.1% during 2012-2015.

Study details: A retrospective study of 2,627 patients with stage IV prostate cancer from the Surveillance, Epidemiology, and End Results-Medicare database, diagnosed between 2007 and 2015. Patients receiving BMAs before the diagnosis or with a history of hypercalcemia, osteoporosis, osteopenia, or bone fracture were not included.

Disclosures: This study was supported by the National Cancer Institute at the National Institutes of Health. The authors received awards, personal/consulting/advisory fees, grants, nonfinancial support, and/or research funding from various sources. Some authors reported stock ownerships in various companies.

Source: Mitchell AP et al. J Natl Cancer Inst. 2021 Oct 1. doi: 10.1093/jnci/djab196.

Key clinical point: Bone-modifying agents (BMAs) are overused in the real world in patients with metastatic castration-sensitive prostate cancer (mCSPC).

Major finding: Receipt of BMAs was reported in 23.6% of patients within 180 days of diagnosis. The proportion of patients receiving BMAs within 180 days increased from 17.3% during 2007-2009 to 28.1% during 2012-2015.

Study details: A retrospective study of 2,627 patients with stage IV prostate cancer from the Surveillance, Epidemiology, and End Results-Medicare database, diagnosed between 2007 and 2015. Patients receiving BMAs before the diagnosis or with a history of hypercalcemia, osteoporosis, osteopenia, or bone fracture were not included.

Disclosures: This study was supported by the National Cancer Institute at the National Institutes of Health. The authors received awards, personal/consulting/advisory fees, grants, nonfinancial support, and/or research funding from various sources. Some authors reported stock ownerships in various companies.

Source: Mitchell AP et al. J Natl Cancer Inst. 2021 Oct 1. doi: 10.1093/jnci/djab196.

Key clinical point: Bone-modifying agents (BMAs) are overused in the real world in patients with metastatic castration-sensitive prostate cancer (mCSPC).

Major finding: Receipt of BMAs was reported in 23.6% of patients within 180 days of diagnosis. The proportion of patients receiving BMAs within 180 days increased from 17.3% during 2007-2009 to 28.1% during 2012-2015.

Study details: A retrospective study of 2,627 patients with stage IV prostate cancer from the Surveillance, Epidemiology, and End Results-Medicare database, diagnosed between 2007 and 2015. Patients receiving BMAs before the diagnosis or with a history of hypercalcemia, osteoporosis, osteopenia, or bone fracture were not included.

Disclosures: This study was supported by the National Cancer Institute at the National Institutes of Health. The authors received awards, personal/consulting/advisory fees, grants, nonfinancial support, and/or research funding from various sources. Some authors reported stock ownerships in various companies.

Source: Mitchell AP et al. J Natl Cancer Inst. 2021 Oct 1. doi: 10.1093/jnci/djab196.

Key clinical point: Androgen-signaling inhibitors (ASIs) are associated with significant survival benefits in patients with metastatic castration-resistant prostate cancer (mCRPC) with luminal tumor subtype.

Major finding: ASI treatment was associated with an improved overall survival in patients with luminal tumors (hazard ratio [HR], 0.27; P < .001), but not in those with basal tumors (HR, 0.62; P = .07).

Study details: A retrospective study of 4 patient cohorts (n=634) with mCRPC.

Disclosures: This study was funded by grants from the Department of Defense, Stand Up To Cancer-Prostate Cancer Foundation, Prostate Cancer Foundation, Movember Foundation, UCSF Benioff, Swedish Research Council, National Cancer Institute, and University of Wisconsin Carbone Cancer Center. The authors received consulting/advisory fees, research funding, and grants outside this work. Some authors reported pending patents and/or being employed with pharmaceutical companies.

Source: Aggarwal R et al. JAMA Oncol. 2021 Sep 23. doi: 10.1001/jamaoncol.2021.3987.

Key clinical point: Androgen-signaling inhibitors (ASIs) are associated with significant survival benefits in patients with metastatic castration-resistant prostate cancer (mCRPC) with luminal tumor subtype.

Major finding: ASI treatment was associated with an improved overall survival in patients with luminal tumors (hazard ratio [HR], 0.27; P < .001), but not in those with basal tumors (HR, 0.62; P = .07).

Study details: A retrospective study of 4 patient cohorts (n=634) with mCRPC.

Disclosures: This study was funded by grants from the Department of Defense, Stand Up To Cancer-Prostate Cancer Foundation, Prostate Cancer Foundation, Movember Foundation, UCSF Benioff, Swedish Research Council, National Cancer Institute, and University of Wisconsin Carbone Cancer Center. The authors received consulting/advisory fees, research funding, and grants outside this work. Some authors reported pending patents and/or being employed with pharmaceutical companies.

Source: Aggarwal R et al. JAMA Oncol. 2021 Sep 23. doi: 10.1001/jamaoncol.2021.3987.

Key clinical point: Androgen-signaling inhibitors (ASIs) are associated with significant survival benefits in patients with metastatic castration-resistant prostate cancer (mCRPC) with luminal tumor subtype.

Major finding: ASI treatment was associated with an improved overall survival in patients with luminal tumors (hazard ratio [HR], 0.27; P < .001), but not in those with basal tumors (HR, 0.62; P = .07).

Study details: A retrospective study of 4 patient cohorts (n=634) with mCRPC.

Disclosures: This study was funded by grants from the Department of Defense, Stand Up To Cancer-Prostate Cancer Foundation, Prostate Cancer Foundation, Movember Foundation, UCSF Benioff, Swedish Research Council, National Cancer Institute, and University of Wisconsin Carbone Cancer Center. The authors received consulting/advisory fees, research funding, and grants outside this work. Some authors reported pending patents and/or being employed with pharmaceutical companies.

Source: Aggarwal R et al. JAMA Oncol. 2021 Sep 23. doi: 10.1001/jamaoncol.2021.3987.

Key clinical point: External beam radiation therapy (EBRT) does not show a survival benefit in newly diagnosed elderly patients with metastatic prostate cancer.

Major finding: Patients who received EBRT vs. those who did not showed similar overall survival (hazard ratio [HR], 0.97; P = .6) and cancer-specific survival (HR, 1.04; P = .4).

Study details: A retrospective study of 6,556 patients, aged 75 years and above, with metastatic prostate cancer identified from the Surveillance, Epidemiology and End Results database between 2004 and 2016, of which 1,105 received EBRT.

Disclosures: No study source was identified for this work. The authors declared no conflict of interests.

Source: Wenzel M et al. Prostate. 2021 Oct 11. doi: 10.1002/pros.24249.

Key clinical point: External beam radiation therapy (EBRT) does not show a survival benefit in newly diagnosed elderly patients with metastatic prostate cancer.

Major finding: Patients who received EBRT vs. those who did not showed similar overall survival (hazard ratio [HR], 0.97; P = .6) and cancer-specific survival (HR, 1.04; P = .4).

Study details: A retrospective study of 6,556 patients, aged 75 years and above, with metastatic prostate cancer identified from the Surveillance, Epidemiology and End Results database between 2004 and 2016, of which 1,105 received EBRT.

Disclosures: No study source was identified for this work. The authors declared no conflict of interests.

Source: Wenzel M et al. Prostate. 2021 Oct 11. doi: 10.1002/pros.24249.

Key clinical point: External beam radiation therapy (EBRT) does not show a survival benefit in newly diagnosed elderly patients with metastatic prostate cancer.

Major finding: Patients who received EBRT vs. those who did not showed similar overall survival (hazard ratio [HR], 0.97; P = .6) and cancer-specific survival (HR, 1.04; P = .4).

Study details: A retrospective study of 6,556 patients, aged 75 years and above, with metastatic prostate cancer identified from the Surveillance, Epidemiology and End Results database between 2004 and 2016, of which 1,105 received EBRT.

Disclosures: No study source was identified for this work. The authors declared no conflict of interests.

Source: Wenzel M et al. Prostate. 2021 Oct 11. doi: 10.1002/pros.24249.

Key clinical point: In patients with localized prostate cancer, robot-assisted laparoscopic prostatectomy (RALP) vs open retropubic radical prostatectomy (RRP) has similar prostate cancer-specific mortality (PCSM) and lower risk for erectile dysfunction in the long term.

Major finding: At 8 years, urinary incontinence was not significantly different between RALP and RRP groups. Erectile dysfunction was significantly lower in the RALP group (66% vs 70%; adjusted risk ratio, 0.93; 95% confidence interval [CI], 0.87-0.99). PCSM was significantly lower in the RALP group (adjusted hazard ratio, 0.56; 95% CI, 0.34-0.93).

Study details: A prospective, controlled, nonrandomized trial of 4,003 patients with localized prostate cancer who were randomly assigned to either RALP and RRP between 2008 and 2011.

Disclosures: This work was supported by the Swedish Cancer Society, Swedish Research Council, Region Västra Götaland, Sahlgrenska University Hospital, Mrs. Mary von Sydow Foundation, Anna and Edwin Berger Foundation, Stockholm County Council, and Swedish Medical Association. The authors declared no competing interests.

Source: Lantz A et al. Eur Urol. 2021 Sep 15. doi: 10.1016/j.eururo.2021.07.025.

Key clinical point: In patients with localized prostate cancer, robot-assisted laparoscopic prostatectomy (RALP) vs open retropubic radical prostatectomy (RRP) has similar prostate cancer-specific mortality (PCSM) and lower risk for erectile dysfunction in the long term.

Major finding: At 8 years, urinary incontinence was not significantly different between RALP and RRP groups. Erectile dysfunction was significantly lower in the RALP group (66% vs 70%; adjusted risk ratio, 0.93; 95% confidence interval [CI], 0.87-0.99). PCSM was significantly lower in the RALP group (adjusted hazard ratio, 0.56; 95% CI, 0.34-0.93).

Study details: A prospective, controlled, nonrandomized trial of 4,003 patients with localized prostate cancer who were randomly assigned to either RALP and RRP between 2008 and 2011.

Disclosures: This work was supported by the Swedish Cancer Society, Swedish Research Council, Region Västra Götaland, Sahlgrenska University Hospital, Mrs. Mary von Sydow Foundation, Anna and Edwin Berger Foundation, Stockholm County Council, and Swedish Medical Association. The authors declared no competing interests.

Source: Lantz A et al. Eur Urol. 2021 Sep 15. doi: 10.1016/j.eururo.2021.07.025.

Key clinical point: In patients with localized prostate cancer, robot-assisted laparoscopic prostatectomy (RALP) vs open retropubic radical prostatectomy (RRP) has similar prostate cancer-specific mortality (PCSM) and lower risk for erectile dysfunction in the long term.

Major finding: At 8 years, urinary incontinence was not significantly different between RALP and RRP groups. Erectile dysfunction was significantly lower in the RALP group (66% vs 70%; adjusted risk ratio, 0.93; 95% confidence interval [CI], 0.87-0.99). PCSM was significantly lower in the RALP group (adjusted hazard ratio, 0.56; 95% CI, 0.34-0.93).

Study details: A prospective, controlled, nonrandomized trial of 4,003 patients with localized prostate cancer who were randomly assigned to either RALP and RRP between 2008 and 2011.

Disclosures: This work was supported by the Swedish Cancer Society, Swedish Research Council, Region Västra Götaland, Sahlgrenska University Hospital, Mrs. Mary von Sydow Foundation, Anna and Edwin Berger Foundation, Stockholm County Council, and Swedish Medical Association. The authors declared no competing interests.

Source: Lantz A et al. Eur Urol. 2021 Sep 15. doi: 10.1016/j.eururo.2021.07.025.